FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		SRL 6067	09/023,401
LIST OF PRIOR ART CITED BY APPLICANT		APPLICANT	
(Use several sh ts if nec ssary)		Gary S. Jacob	
Ant in 09/249,220?		FILING DATE	GROUP
		2-12-98	1614

OIPE AUG 14 2000 PATENT & TRADEMARK OFFICE 95CJ

RECEIVED AUG 16 2000 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	27	3,590,028	6/1971	Arcamone	260	210	
	28	4,012,448	3/1977	Smith et al.	260	591	
	29	4,065,562	12/1977	Ohata et al.	424	267	
	30	4,182,767	1/1980	Murai et al.	424	267	
	31	4,260,622	4/1981	Junge et al.	424	267	
	32	4,327,725	5/1982	Cortese et al.	128	260	
	33	4,524,060	6/1985	Mughal et al.	424	19	
	34	4,533,668	8/1985	Matsumura et al.	514	321	
	35	4,611,058	9/1986	Koebernick	546	242	
	36	4,612,008	9/1986	Wong et al.	604	892	
	37	4,765,989	8/1988	Wong et al.	424	473	
	38	4,783,337	11/1988	Wong et al.	424	468	
	39	4,806,650	2/1989	Schröder et al.	546	242	
	40	4,849,430	7/1989	Fleet et al.	514	315	
	41	4,880,830	11/1989	Rhodes	424	470	
	42	4,957,926	9/1990	Jacob et al.	514	315	
	43	5,003,072	3/1991	Partis et al.	546	243	
	44	5,011,829	4/1991	Hirsch et al.	514	50	
	45	5,030,638	7/1991	Partis et al.	514	315	
	46	5,041,441	8/1991	Radin et al.	514	237.8	
	47	5,068,112	11/1991	Samejima et al.	424	495	
	48	5,190,765	3/1993	Jao et al.	424	473	
	49	5,144,037	9/1992	Partis et al.	546	116	

EXAMINER	DATE CONSIDERED 7/26/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Use sev ral sh ets if n cessary)		APPLICANT Gary S. Jacob	
		FILING DATE 2-12-98	GROUP 1614

	50	5,151,519	9/1992	Behling et al.	546	219	
	51	5,281,724	1/1994	Behling et al.	549	334	
	52	5,310,745	5/1994	Partis et al.	514	315	
	53	5,331,096	7/1994	Koszyk et al.	546	115	
	54	5,411,970	5/1995	Partis et al.	514	315	
	55	5,451,679	9/1995	Barta et al.	546	219	
	56	5,472,969	12/1995	Platt et al.	514	315	
	57	5,491,135	2/1996	Blough	514	115	
	58	5,525,616	6/1996	Platt et al.	514	315	
	59	5,536,732	7/1996	Lesur et al.	514	317	
	60	5,595,981	1/1997	Barta et al.	514	63	
	61	5,612,480	3/1997	Barta et al.	544	180	
	62	5,663,342	9/1997	Barta et al.	546	6	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	63	2,020,278	3/1979	U.K.	C07D	211/40		
	64	0 324 328	7/1989	EPO	A61K	31/445		
	65	0 350 012	1/1990	EPO	A61K	31/445		
	66	0 367 748	5/1990	EPO	C07D	211/46		
	67	0 449 026	10/1991	EPO	C07D	491/04		
	68	0 494 850	7/1992	EPO	C07D	211/46		
	69	0 566 556	10/1993	EPO	C07D	211/40		
	70	WO87/03903	7/1987	PCT	C12N	05/00		
	71	WO95/22975	8/1995	PCT	A61K	31/445		
	72	WO96/40110	12/1996	PCT	A61K	31/35		

EXAMINER	DATE CONSIDERED 3/26/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		SRL 6067	09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Us sev ral sh ts if nec ssary)	OIPE AUG 14 2000 PATENT & TRADEMARK OFFICE	APPLICANT Gary S. Jacob	
		FILING DATE 2-12-98	GROUP 1614

	73	WO97/00881	1/1997	PCT	C07H	17/02		No
	74	WO98/35685	8/1998	PCT	A61K	31/70		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	75	Dalton, et al., "A Phase II Randomized Study of Oral Verapamil as a Chemosensitizer to Reverse Drug Resistance in Patients with Refractory Myeloma," February 1, 1995, Cancer, Vol. 75, No. 3, pp. 815-820
	76	Jacob et al., "Aminosugar Attenuation of HIV Infection," 1992, Natural Products as Antiviral Agents, pp. 137-152
	77	Karpas, et al., "Aminosugar Derivatives as Potential Anti-Human Immunodeficiency Virus Agents," December, 1988, Proc. Natl. Acad. Sci., Vol. 85, pp. 9229-9233
	78	Welsh, et al., "Accumulation of Fatty Alcohol in MCF-7 Breast Cancer Cells," November 15, 1994, Archives of Biochemistry and Biophysics, Vol. 315, No. 1, pp. 41-47
	79	Lavie, et al., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells," August 20, 1996, The Journal of Biological Chemistry, Vol. 272, No. 3, pp. 1682-1687
	80	Lavie et al., "Accumulation of Glucosylceramides in Multidrug-Resistant Cancer Cells," August 9, 1996, The Journal of Biological Chemistry, Vo. 271, No. 32, pp. 19530-19536
	81	Inokuchi, et al., "Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis," September 3, 1987, Cancer Letters, Vol. 38, pp. 23-30
	82	Holleran, et al., "Characterization of Cellular Lipids in Doxorubicin-Sensitive and -Resistant P388 Mouse Leukemia Cells," 1986, Cancer Chemother Pharmacol, 17:11-15
	83	Fisher, et al., "Clinical Studies with Modulators of Multidrug Resistance," April 1995, Drug Resistance in Clinical Oncology and Hematology, Vol. 9, No. 2, pp. 363-382
	84	Raderer, et al., "Clinical Trials of Agents that Reverse Multidrug Resistance," December 15, 1993, Cancer, Vol. 72, No. 12, pp. 3553-3563
	85	Tan, et al., "Chemical Modification of the Glucosidase Inhibitor 1-Deoxynojirimycin," August 5, 1991, The Journal of Biological Chemistry, Vo. 266, No. 22, pp. 14504-14510
	86	Wang, et al., "Chemo-enzymatic Synthesis of Five-membered Azasugars as Inhibitors of Fucosidase and Fucosyltransferase: An Issue Regarding The Stereochemistry Discrimination at Transition States," 1993, Tetrahedron Letters, Vol. 34, No. 3, pp. 403-406
	87	Jezowska-Bojczuk, et al., "Copper(II) Interactions with an Experimental Antiviral Agent, 1-Deoxynojirimycin, and Oxygen Activation by Resulting Complexes," 1996, Journal of Inorganic Biochemistry, Vol. 64, pp. 231-246
	88	Ramu, et al., "Differences in Lipid Composition of Doxorubicin-Sensitive and -Resistant P388 Cells," April 1984, Cancer Treatment Reports, Vol. 68, No. 4, pp. 637-641

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		SRL 6067	09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Gary S. Jac b	
		FILING DATE 2-12-98	GROUP 1614

OIPE AUG 14 2000 JC56 PATENT & TRADEMARK OFFICE

	89	Beketic-Oreskovic, et al., "Decreased Mutation Rate for Cellular Resistance to Doxorubicin and Suppression of mdr1 Gene Activation by the Cyclosporin PSC 833," November 1, 1995, Journal of the National Cancer Institute, Vol. 87, No. 21, pp. 1593-1602
	90	Volm, et al., "Expression of Resistance Factors (P-Glycoprotein, Glutathione S-Transferase-∏, and Topoisomerase II) and Their Interrelationship to Proto-Oncogene Products in Renal Cell Carcinomas," June 15, 1993, Cancer, Vol. 71, No. 12, pp. 3981-3987
	91	Lu, et al., "Evidence That N-Linked Glycosylation is Necessary for Hepatitis B Virus Secretion," November 10, 1995, Virology, Vol. 213, No. 2, pp. 660-665
	92	Legler, et al., "Glycosylceramidase from Calf Spleen: Characterization of its Active Site with 4-n-Alkylurnbelliferyl β-glucoside and N-alkyl Derivatives of 1-Deoxynojirimycin," December 1985, Bio-ChemHoppe-Seyler, Vol. 366, pp. 1113-1122
	93	Hardman, et al., "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 1996, McGraw-Hell, Ninth Edition, Chapter 32: Drugs Used for the Treatment of Myocardial Ischemia," Verepemil, pp. 767-774, 780-781, 799-801, and 829
	94	Mehta, et al., Hepatitis B Virus (HBV) Envelope Glycoproteins Vary Drastically in Their Sensitivity to Glycan Processing: Evidence that Alteration of a Single N-Linked Glycosylation Site Can Regulate HBV Secretion," March 1997, Proc. Natl. Acad. Sci., Vol. 94, pp. 1822-1827
	95	Hollinger, "Hepatitis B Virus," Field Virology, Third Edition, Chapter 86, pp. 2739-2807
	96	Fleet, et al., "Inhibition of HIV Replication by Amino-Sugar Derivatives," September 1988, Federation of European Biochemical Societies, Vol. 237, No. 1,2, pp. 128-132
	97	Newbrun, et al., "Inhibition by Acarbose, Nojirimycin and 1-Deoxynojirimycin of Glucosyltransferase Produced by Oral *Streptococci*, " 1983, Archs Oral Biol., Vol. 28, No. 6, pp. 531-536
	98	Saunier, et al., "Inhibition of N-Linked Complex Oligosaccharide Formation by 1-Deoxynojirimycin, An Inhibitor of Processing Glucosidases," December 10, 1982, The Journal of Biological Chemistry, Vol. 257, No. 23, pp. 14155-14161
	99	Abe, et al., "Induction of Glycosylceramide Synthase by Synthase Inhibitors and Ceramide," 1996, Biochemica et Biophysica Acta, Vol. 1299, pp. 333-341
	100	Abe, et al., "Improved Inhibitors of Glucosylceramide Synthase," 1992, J. Biochem., Vol. 111, pp. 191-196
	101	Elbein, "Inhibitors of the Biosynthesis and Processing of N-Linked Oligosaccharide Chains," 1987, Ann. Rev. Biochem., 56:497-534
	102	Radin, et al., "Inhibitors of Cerebroside Metabolism," 1981, Methods in Enzymology, Vol. 72, pp. 673-684
	103	Prence, et al., "In Vitro Accumulation of Glucocerebroside in Neuroblastoma Cells: A Model for Study of Gaucher Disease Pathobiology," 1996, Journal of Neuroscience Research, 43:365-371

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		SRL 6067	09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Gary S. Jacob	
		FILING DATE: 2-12-98	GROUP: 1614

	104*	Bradley, et al., "Mechanism of Multidrug Resistance," 1988, Biochimica et Biophysica Acta, Vol. 948, pp. 87-128
	105*	Mulder, et al., "Multidrug Resistance-Modifying Components in Human Plasma with Potential Clinical Significance," January 1996, Journal of Experimental Therapeutics & Oncology, Vol. 1, No. 1, pp. 13-22
	106	Ardalan, et al., "Mechanism of Action of a New Antitumor Agent, Carbetimer," November 1986, Cancer Research, Vol. 46, pp. 5473-5476
	107	Platt, et al., "Modulation of Cell Surface Transferrin Receptor by the Imino Sugar N-butyldeoxynojirimycin," 1992, Eur. J. Biochem., Vol. 208, pp 187-193
	108	Kawakami, et al., "Monoclonal Antibodies with Affinity to Self-Complementary Left-Handed DNA Containing Cyclonucleosides with High Anti Conformation," 1994, Nucleosides & Nucleotides, Vol. 13(1-3), pp. 421-427
	109	Dicato, et al., "Multidrug Resistance: Molecular and Clinical Aspects," 1997, Cytokines, Cellular & Molecular Therapy, Vol. 3, No. 2, pp. 91-100
	110	Bolhuis, et al., "Mechanisms of Multidrug Transporters," 1997, FEMS Microbiology Reviews, Vol. 21, pp. 55-84
	111	Carbohydrate Chemistry, "Chapter 20: Nucleosides," undated, pp. 242-276
	112	Platt, et al., "N-Butyldeoxynojirimycin Is a Novel Inhibitor of Glycolipid Biosynthesis," March 18, 1994, The Journal of Biological Chemistry, Vol. 269, No. 11, pp. 8362-8365
	113	Platt, et al., "N-Butyldeoxygalactonojirimycin Inhibits Glycolipid Biosynthesis but Does Not Affect N-Linked Oligosaccharide Processing," October 28, 1994, The Journal of Biological Chemistry, Vol. 269, No. 43, pp. 27108-27114
	114	Platt, et al., "New Approach for the Treatment of Gauchers Disease," March 1996, Gauchers Association Newsletter, one page
	115	Wilson, et al., "Nitrogen Glycosylation Reactions Involving Pyrimidine and Purine Nucleoside Bases with Furanoside Sugars," December 1995, Synthesis, Department of Chemistry, Emory University, pp. 1465-1479
	116	Kers, et al., "Nucleoside Phosphonates: Development of Synthetic Methods and Reagents," 1996, Nucleosides & Nucleotides, 15(1-3), pp. 361-378
	117	Tsuruo, et al., "Overcoming of Vincristine Resistance in P388 Leukemis *In Vivo* and *In Vitro* Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil," May 1981, Cancer Research, Vol. 41, pp. 1967-1972
	118	Wright, et al., "Phospholipid and Ether Linked Phospholipid Content Alter with Cellular Resistance to Vinblastine," December 17, 1985, Biochemical and Biophysical Research Communications, Vol. 133, No. 2, pp. 539-545
	119	Bradley, et al., "P-glycoprotein, Multidrug-Resistance and Tumor Progression," 1994, Cancer and Metastasis Reviews, Vol. 13, pp. 223-233
	120	May, et al., "Plasma Membrane Lipid Composition of Vinblastine Sensitive and Resistant Human Leukaemic Lymphoblasts," 1988, Int. J. Cancer, Vol. 42, pp. 728-733

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		SRL 6067	09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	OIPE JC56 AUG 14 2000 PATENT & TRADEMARK OFFICE	APPLICANT: Gary S. Jacob	
		FILING DATE: 2-12-98	GROUP: 1614

	121	Platt, et al., "Prevention of Lysosomal Storage in Tay-Sachs Mice Treated with N-Butyldeoxynojirimycin," April 18, 1997, Science, Vol. 276, pp. 428-431
	122	Wishart, et al., "Quinidine as a Resistance Modulator of Epirubicin in Advanced Breast Cancer: Mature Results of a Placebo-Controlled Randomized Trial," September 1994, Journal of Clinical Oncology, Vol. 12, No. 9, pp. 1771-1777
	123	Chabner, et al., "Reversal of Multidrug Resistance," January 1991, Journal of Clinical Oncology, Vol. 9, No. 1, pp. 4-6
	124	Hui, et al., "Reduced p21$^{WAF1/CIP1}$ Expression and p53 Mutation in Hepatocellular Carcinomas," March 1997, Hepatology, Vol. 25, No. 3, pp. 575-579
	125	Radin, "Rationales for Cancer Chemotherapy with PDMP, a Specific Inhibitor of Glucosylceramide Synthase," 1994, Molecular and Chemical Neuropathology, Vol. 21, pp. 111-127
	126	Arends, "Recueil des Travaux Chimiques des Pays-Bas," Journal of the Royal Netherlands Chemical Society, February 1994, Recl. Trav. Chim. Pays-Bas 113, 63-114, contents page only
	127	Shukla, et al., "Rapid Kidney Changes Resulting from Glycosphingolipid Depletion by Treatment with a Glucosyltransferase Inhibitor," 1991, Biochemica et Biophysica Acta., Vol. 1083, pp. 101-108
	128	Block, et al., "Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar N-butyldeoxynojirimycin," March 1994, Proc. Natl. Acad. Sci., Vol. 91, pp.2235-2239
	129	Inokuchi, et al., "Stimulation of Glycosphingolipid Biosynthesis by L-*Threo*-1-Phenyl-2-Decanoylamino-1-Propanal and Its Homologs in B16 Melanoma Cells," 1995, J. Biochem., Vol. 117, No. 4, pp. 766-773
	130	Abe, et al., "Structural and Stereochemical Studies of Potent Inhibitors of Glucosylceramide Synthase and Tumor Cell Growth," 1995, Journal of Lipid Research, Vol. 36, pp. 611-621
	131	Ogawa, et al., "Synthesis of Potent β-D-Glucocerebrosidase Inhibitors: N-Alkyl-β-Valienamines," 1996, Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 8, pp. 929-932
	132	Vorbrüggen, et al., "Some Recent Trends and Progress in Nucleoside Synthesis," 1996, Acta Biochimica Polonica, Vol. 43, No. 1, pp. 25-36
	133	Sobrero, et al., "Sequential Dichloromethotrexate (DCM) and 5-Fluorouracil (FU): A Synergistic Combination Potentially Valuable for Hepatic Artery Infusion Therapy," March 1983, ASCO Abstracts, Clinical Pharmacology, Vol. 2, Article C-102, p. 26
	134	Wadkins, et al., "The Role of Drug-Lipid Interactions in the Biological Activity of Modulators of Multi-Drug Resistance," 1993, Biochimica et Biophysica Acta, Vol. 1153, pp. 225-236
	135	Doige, et al., "The Effects of Lipids and Detergents on ATPase-Active P-Glycoprotein," 1993, Biochimica et Biophysica Acta, Vol. 1146, pp. 65-72
	136	Ries, et al., "Treatment of Advanced and Refractory Breast Cancer with Doxorubicin, Vincristine and Continuous Infusion of Verapamil. A Phase I-II Clinical Trial," 1991, Med. Oncol. & Tumor Pharmacother, Vol. 8, No. 1, pp. 39-43

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		SRL 6067	09/023,401
LIST OF PRIOR ART CITED BY APPLICANT (Us several sheets if nec ssary)		APPLICANT Gary S. Jac b	
		FILING DATE 2-12-98	GROUP 1614

OIPE JC56 AUG 14 2000 PATENT & TRADEMARK OFFICE

	137	Radin, et al., "Treatment of Gaucher Disease with an Enzyme Inhibitor," 1996, Glycoconjugate Journal, Vol. 13, pp. 153-157
	138	Fischl, et al., "The Safety and Efficacy of Combination N-Butyl-Deoxynojirimycin (SC-48334) and Zidovudine in Patients with HIV-1 Infection and 20--500 CD4 Cells/mm^3," 1994, Journal of Acquired Immune Deficiency Syndromes, Vol. 7, pp. 139-147
	139	Block, et al., "The Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar, N-Butyl-Deoxynojirimycin," undated, Jefferson Cancer Institute, et al., No. 81, one page
	140	Mutchnick, et al., "Thymosin Treatment of Chronic Hepatitis B: A Placebo-controlled Pilot Trial," 1991, Hepatology, Vol. 14, No. 3, pp. 409-415
	141	Simon, et al., "Treatment of Chronic Hepatitis C with Interferon Alfa-n3: A Multicenter, Randomized, Open-Label Trial," February 1997, Hepatology, Vol. 25, No. 2, pp. 445-448
	142	Cabot, et al., "Tamoxifen Retards Glycosphingolipid Metabolism in Human Cancer Cells," 1996, FEBS Letters (17548), Vol. 394, pp. 129-131
	143	Lindsay, et al., "Thymosin α_1 Treatment of Chronic Hepatitis B: A Multicenter, Randomized, Placebo-Controlled Double Blind Study," April 1995, AASLD, A1127, one page
	144	Mutchnick, et al., "Thymosin Treatment of Chronic Active Hepatitis B (CAHB): A Preliminary Report on a Controlled, Double Blind Study," 1988, Hepatology, Vol. 8, No. 5, Article 208, p. 1270
	145	Dwek, Raymond, "Glycobiology: Toward Understanding the Function of Sugars," Chem. Rev. 1996, 96, pp. 683-720
	146	Platt, Frances M., et al., "Inhibitors of Glycosphingolipid Biosynthesis," Trends in Glycoscience and Glycotechnology, Vol. 7, No. 38, November 1995, pp. 495-511

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80) COMMERCE

U.S. DEPARTMENT OF PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.
SRL 6067	09/023,401
APPLICANT: Gary S. Jacobs et al.	
FILING DATE: February 12, 1998	GROUP: 1614

OIPE JC157 JUL 19 2001 PATENT & TRADEMARK OFFICE

RECEIVED JUL 23 2001 TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(Use several sheets if necessary)

Sheet 1 of 3

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
b	147	4,269,857	5/1981	Tokuda et al.	424	325	
b	148	5,221,746	6/1993	Partis et al.	546	220	
	149	5,264,356	11/1993	Rohrschneider	435	236	
	150	5,622,972	4/1997	Bryant et al.	514	315	
	151	5,703,058	12/1997	Schinazi et al.	514	45	
	152	6,093,702	7/2000	Malley et al.	514	45	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	153	2,700,267	1/1993	FR	A61K	9/107		
	154	0 401 194	6/1990	EPO	A61K	31/70		
	155	0 477 160	9/1991	EPO	C12P	17/04		
	156	0 691 327	3/1994	EPO	C07C	217/28		
	157	0 729 747	2/1996	EPO	A61K	7/48		
	158	WO91/17145	11/1991	PCT	C07D	211/46		
	159	WO94/04546	3/1994	PCT	C07H	17/02		Abstract
	160	WO95/06061	3/1995	PCT	C07K	5/03		
	161	WO99/29321	6/1999	PCT	A61K	31/445		
	162	WO99/40916	8/1999	PCT	A61K	31/445		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	163	Acosta et al., "Agents for Treating Human Immunodeficiency Virus Infection," Am. J. Hosp. Pharm., Vol. 51, September 15, 1994, pp. 2251-2287
	164	Tennant et al., "Animal Models in the Preclinical Assessment of Therapy for Viral Hepatitis," Antiviral Therapy, Vol. 1, (Suppl. 4), 1996, pp. 47-52

EXAMINER	DATE CONSIDERED 9/26/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 COMMERCE (REV. 7-80)	U.S. DEPARTMENT OF PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
		APPLICANT Gary S. Jacob et al.	
		FILING DATE February 12, 1998	GROUP 1614

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)
(Use several sheets if necessary)

Sheet 2 of 3

OIPE JC157 JUL 19 2001 PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900 JUL 23 2001

	165	Sachs, "Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than with Azidothymidine," Arch. Inter. Med., Vol. 152, March 1992, pp. 485-501
	166	Gasparini, et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool," Journal of Clinical Oncology, Vol. 13, No. 3, March 1995, pp. 765-782
	167	Bruyneel, et al., "Effect of Glycosylation Inhibitors on N-Glycosylpeptides and on Invasion of Malignant Mouse MO_4 Cells in Vitro," Journal of Cell Science, Vol. 95, 1990, pp. 279-286
	168	Jacob, "Glycosylation Inhibitors in Biology and Medicine," Current Opinion in Structural Biology, No. 5, 1995, pp. 605-611
	169	Senuma, et al., "Highly Effective Resolution of 1,3-Dibensl-6-hydroxy-3,3a,6,6a-tetrahydro-1H-furo[3,4-d]imidazole-2,4-dione, an Intermediate for Biotin, with Optically-Active Amines and Reutilization of the Unwanted Epimer," Chem. Pharm. Bull., Vol. 38, No. 4, 1990, pp. 882-887
	170	Zitzmann, et al., "Imino Sugars Inhibit the Formation and Secretion of Bovine Viral Diarrhea Virus, a Pestivirus Model of Hepatits C Virus: Implications for the Development of Broad Spectrum Anti-Hepatitis Virus Agents," PNAS, Vol. 96, No. 21, October 12, 1999, pp. 11878-11882
	171	Jacob, et al., "Iminosugar alpha-Glucosidase Inhibitors as Drugs and Pro-Drugs for Treatment of HIV Infections," Washington Book of Abstracts, 208th ACS National Meeting, August 21-25, 1994, one page
	172	Rusconi, et al., "Inhibition of Human Immunodeficiency Virus Type I Replication in Cytokine-Stimulated Monocytes/Macrophages by Combination Therapy," Journal of Infectious Diseases, Vol. 170, 1994, pp. 1361-1366
	173	Goss, et al., "Inhibitors of Carboyhydrate Processing: A New Class of Anticancer Agents," Clinical Cancer Research, Vol. 1, September 1995, pp. 935-944
	174	Isom, et al., "Molecular Pathology of Human Oncogenic Viruses," Cellular and Molecular Pathogenesis, Chapter 14, 1996, pp. 341-387
	175	Ratner, et al., "Mechanism of Action of N-Butyl Deoxynojiriimycin in Inhibiting HIV-1 Infection and Activity in Combination with Nucleoside Analogs," AIDS Research and Human Retroviruses, Vol. 9, No. 4, 1993, pp. 291-297
	176	Myers, "New Antiretroviral Agents in the Clinic," Reviews of Infectious Diseases, Vol. 12, No. 5, September/October 1990, pp. 944-950
	177	Yangco, et al., "Pilot Safety and Efficacy of Combination SC-48334 (N-Butyl-Deoxynijirimycin (NB-DNJ) and Zidovudine (ZDA) in Symptomatic HIV-1 Infected Patients with ≥ 200 - ≤ 500 CD4 Cells/mm^3," Abstracts of the 1st National Conference on Human Retroviruses, Session 86, Abstract No. 574, p. 160
	178	van den Broek, et al., "Synthesis of Oxygen-Substituted N-alkyl 1-deoxynojirimycin derivatives: aza sugar α-glucosidase inhibitors showing antiviral (HIV-1) and immunosuppressive activity," Recl. Trav. Chim. Pays-Bas 113, 1994, pp. 507-516
	179	Mitts, et al., "The Reaction of Glucose with Some Amines," Journal of the American Chemical Society, Vol. 66, March 1944, pp. 483-486
	180	Fischl, et al., "The Preliminary Efficacy and Safety of N-Butyl-Deoxynojirimycin (SC-48334), an alpha-Glucosidase I Inhibitor, in Combination with Zidovudine (ZDA)," International Conference on AIDS, Berlin, June 6-11, 1993, one page

EXAMINER	DATE CONSIDERED 9/26/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 COMMERCE (REV. 7-80)	U.S. DEPARTMENT OF PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SRL 6067	SERIAL NO. 09/023,401
INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) (Use several sheets if necessary) Sheet 3 of 3		APPLICANT Gary S. Jacob et al.	
		FILING DATE February 12, 1998	GROUP 1614

OIPE JC157 JUL 19 2001 PATENT & TRADEMARK OFFICE

RECEIVED JUL 23 2001 TECH CENTER 1600/2900

	181	Iino, "Treatment of Chronic Viral Hepatitis," Mol. Med. (Tokyo), 1996, Vol. 33, No. 3, pp. 276-286 (English language abstract only)
	182	Fiume, et al., "Targeting of Antiviral Drugs to the Liver Using Glycoprotein Carriers," Advanced Drug Delivery Reviews, Vol. 14, 1994, pp. 51-65
	183	Mutchnick, et al., "Thymosin Treatment of Chronic Active Hepatitis B (CAHB): A Preliminary Report on a Controlled, Double Blind Study," 1988, Hepatology, Vol. 8, No. 5, Article 208, p. 1270
	184	Jones, et al., "Use of the Topliss Scheme for the Design of More Effective Chelating Agents for Cadmium Decorporation," Chem. Res. Toxicol., Vol. 1, 1988, pp. 234-237
	185	Karrer, et al., "Zur Kenntis der Reduktionsprodukte aus Aromatischen Aminen und Zuckern," 1935, p. 1338-1340

EXAMINER	DATE CONSIDERED 7/26/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.